A new study has identified a promising strategy to improve natural killer (NK) cell therapy for pancreatic cancer, one of the deadliest and most treatment-resistant cancers. Pancreatic tumors often evade immune attack by using HLA class I molecules to suppress NK cell activity, allowing cancer cells to survive and grow.
Researchers found that using HLA-mismatched donor NK cells can overcome this defense mechanism. Unlike matched NK cells, which can be switched off by the tumor, mismatched and “educated” donor NK cells remain active because they do not recognize the tumor’s inhibitory signals. As a result, they respond more strongly to stress signals from cancer cells and attack the tumor more effectively.
In a humanized mouse model of pancreatic cancer, these mismatched NK cells achieved better tumor control than matched NK cells and did not cause damage to healthy tissues. The findings suggest that donor-derived NK cell therapies could offer a safer and more effective treatment option for pancreatic cancer.
Researchers are now exploring ways to optimize donor selection and develop combinations of NK cell subtypes to further enhance the therapy’s effectiveness against aggressive solid tumors.